NRCAM

Across TCGA pan-cancer cohorts, NRCAM mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NRCAM data layer compared with 24 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher NRCAM mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NRCAM expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, HNSC, and GBM are the cancer types where NRCAM mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.802	0.468	.002	13	view →
HNSC	OS	Quartile	III,IV	0.835	0.566	.033	3	view →
GBM	OS	Quartile	All	0.652	0.424	.033	2	view →
CCRCC	OS	Tertile	All	0.669	1.000	.023	1	view →
LSCC	DFS	Median	II,III,IV	0.861	0.680	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NRCAM–LUAD (DFS)

Open the LUAD breakdown →